Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability
Janssen Has First Combo Data, With Its Own Darzalex
Executive Summary
Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.